Serial 97494522
Live / Registered — Registered (as of 01 Aug 2023)
What this means for you
Registered since 01 Aug 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97494522
- Registration number
- 7127089
- Mark type
- Design / logo
- Filed
- 08 Jul 2022
- Published for opposition
- 16 May 2023
- Registered
- 01 Aug 2023
- Attorney of record
- Jared M. Barrett
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of kidney disease; pharmaceutical preparations for the treatment of focal segmental glomerulosclerosis (FSGS); pharmaceutical preparations for the treatment of Immunoglobulin A Nephropathy (IgAN); pharmaceutical preparations for the treatment of Alport Syndrome; pharmaceutical preparations for the treatment of glomerulonephropathy; pharmaceutical preparations for the treatment of glomerulonephritis
Owner
- Travere Therapeutics, Inc., San Diego, CA, US
- Travere Therapeutics, Inc., San Diego, CA, US
- Travere Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 01 Aug 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 01 Aug 2023 — REGISTERED-PRINCIPAL REGISTER
- 16 May 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 May 2023 — PUBLISHED FOR OPPOSITION
- 26 Apr 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 Apr 2023 — NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
- 12 Apr 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 Apr 2023 — USE AMENDMENT ACCEPTED
- 04 Apr 2023 — ASSIGNED TO EXAMINER
- 23 Feb 2023 — AMENDMENT TO USE PROCESSING COMPLETE
- 23 Feb 2023 — USE AMENDMENT FILED
- 22 Feb 2023 — TEAS AMENDMENT OF USE RECEIVED
- 28 Jul 2022 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 27 Jul 2022 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 12 Jul 2022 — NEW APPLICATION ENTERED